Form 4: Nuvation Bio Inc. Executive Acquires 500,000 Stock Options
SEC Form 4 Filing
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., acquired 500,000 stock options on February 28, 2025, according to a Form 4 filing with the SEC.
Summary
- Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio Inc. (NUVB), filed a Form 4 with the SEC.
- The filing reports the acquisition of 500,000 stock options on February 28, 2025.
- The exercise price of each option is $1.97.
- The options vest as to 25% on the one-year anniversary of February 28, 2025, and then monthly over the following 36 months, contingent upon continuous service.
- The expiration date for the options is February 27, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative from an investment perspective. It's a neutral event.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, like officers and directors, trade in their company's securities. This filing indicates an acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in the biotechnology industry, often used to align management's interests with those of shareholders.
- The vesting schedule of 25% after one year and then monthly over the following 36 months is a typical vesting arrangement.
- Comparing the size of this option grant to similar companies and executive roles would require further analysis of Nuvation Bio's compensation policies and industry benchmarks.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, incentivizing them to increase the company's value.
- The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's overall share count.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of earliest transaction: acquisition of stock options. |
| 02/28/2025 | First vesting date: 25% of options vest one year after this date. |
| 02/27/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.